Science

Pipeline

 

COVID-19 IgG Therapy

  •  
  • Phase I
  • Phase II
  • Phase III
Available for clinical and compassionate use

Therapeutic Area: COVID-19

Partnered with Kedrion Biopharma for global activity.

Inhaled AAT

  •  
  • Phase I
  • Phase II
  • Phase III
US Phase 2 (completed)
Phase 3 initiated in EU, FDA acceptance of path forward

Therapeutic Area: AAT Deficiency

EMA accept new Ph3 design, FDA acceptance of Inhaled AAT program path forward.
May seek partner upon IND/CTA approval.

Recombinant AAT

  •  
  • Phase I
  • Phase II
  • Phase III
Early Development

Therapeutic Area: AAT Deficiency

Early stage development.

AAT (liquid)

  •  
  • Phase I
  • Phase II
  • Phase III
Ex-Vivo study

Therapeutic Area: Organ preservation

In collaboration with Massachusetts General Hospital.

Kamada is at the forefront of clinical research for plasma-derived proteins and additional therapeutic indications for Alpha-1 Antitrypsin (AAT).